prikaz prve stranice dokumenta Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials
  Download
PDF 2.17 MB
Scientific paper - Original scientific paper
Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials
BMJ Open, 8 (2018), 11; 1-9. https://doi.org/10.1136/bmjopen-2018-021508
Sahebkar, Amirhossein; Simental-Mendía, Luis E; Katsiki, Niki; Reiner, Željko; Banach, Maciej; Pirro, Matteo; Atkin, Stephen L

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Sahebkar, A., Simental Mendía, L. E., Katsiki, N., Reiner, Ž., Banach, M., Pirro, M. & Atkin, S. L. (2018). Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials. BMJ Open, 8. (11), 1-9. doi: 10.1136/bmjopen-2018-021508

Sahebkar, Amirhossein, et al. "Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials." BMJ Open, vol. 8, no. 11, 2018, pp. 1-9. https://doi.org/10.1136/bmjopen-2018-021508

Sahebkar, Amirhossein, Luis E Simental Mendía, Niki Katsiki, Željko Reiner, Maciej Banach, Matteo Pirro and Stephen L Atkin. "Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials." BMJ Open 8, no. 11 (2018): 1-9. https://doi.org/10.1136/bmjopen-2018-021508

Sahebkar, A., et al. (2018) 'Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials', BMJ Open, 8(11), pp. 1-9. doi: 10.1136/bmjopen-2018-021508

Sahebkar A, Simental Mendía LE, Katsiki N, Reiner Ž, Banach M, Pirro M, and sur.. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials. BMJ Open [Internet]. 2018 [cited 2024 December 25];8(11):1-9. doi: 10.1136/bmjopen-2018-021508

A. Sahebkar, et al., "Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials", BMJ Open, vol. 8, no. 11, pp. 1-9, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:905155. [Accessed: 25 December 2024]

Metadata
Title (english)Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta- analysis of randomised placebo-controlled trials
AuthorAmirhossein Sahebkar
AuthorLuis E Simental-Mendía
AuthorNiki Katsiki
AuthorŽeljko Reiner
AuthorMaciej Banach
AuthorMatteo Pirro
AuthorStephen L Atkin
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Objectives This meta-analysis of randomised placebo-controlled clinical trials aimed to assess the effect of fenofibrate on apolipoprotein C-III (apo C-III), a key regulator of triglyceride metabolism. Materials and methods Randomised placebo- controlled trials investigating the impact of fenofibrate treatment on apo C-III levels were searched in PubMed-Medline, Scopus, Web of Science and Google Scholar databases from inception to 18 August 2017. Quantitative data synthesis was determined by a random-effects model and generic inverse variance method. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate glycaemic parameter confounders. Results Meta-analysis of 10 clinical trials involving 477 subjects showed fenofibrate therapy decreased apo C-III levels (weighted mean difference (WMD) -4.78mg/dL, 95% CI -6.95 to -2.61, p<0.001 ; I(2)66.87%). Subgroup analysis showed that fenofibrate reduced plasma apo C-III concentrations in subgroups of trials with treatment durations of either <12 weeks (WMD -4.50mg/dL, p=0.001) or 12 weeks (WMD: -4.73mg/dL, p=0.009) and doses of fenofibrate <200mg/day (WMD -6.33mg/dL, p<0.001) and >200mg/day (p=0.006), with no significant difference between the subgroups. Conclusion This meta-analysis found that fenofibrate therapy significantly decreases apo C-III levels, an effect evident with both short-term treatment and doses less than 200mg/day.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBMJ Open
Numberingvol. 8, no. 11, pp. 1-9
p-ISSN2044-6055
DOIhttps://doi.org/10.1136/bmjopen-2018-021508
URN:NBNurn:nbn:hr:184:905155
Publication2018
Document URLhttp://bib.irb.hr/1050163
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2022-02-17 15:35:40